https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-12-22 / Integr Cancer Ther 2019 Jan-Dec;18:1534735418812691
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-12-22 / Integr Cancer Ther 2019 Jan-Dec;18:15347354188126912018-12-22 00:00:002018-12-22 00:00:00Modulated Electrohyperthermia in Integrative Cancer Treatment for Relapsed Malignant Glioblastoma and Astrocytoma: Retrospective Multicenter Controlled Study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-12-05 / Acta Neuropathol Commun 2018 12;6(1):135
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-12-05 / Acta Neuropathol Commun 2018 12;6(1):1352018-12-05 00:00:002018-12-05 00:00:00Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-11-12 / Cancers (Basel) 2018 Nov;10(11)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-11-12 / Cancers (Basel) 2018 Nov;10(11)2018-11-12 00:00:002019-02-15 08:47:42The Dilemma of Cure and Damage in Oligodendroglioma: Ways to Tip the Balance Away from the Damage
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-09-26 / Cancers (Basel) 2018 Sep;10(10)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-09-26 / Cancers (Basel) 2018 Sep;10(10)2018-09-26 00:00:002018-09-26 00:00:00The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-29 / CNS Oncol 2018 07;7(3):CNS22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-29 / CNS Oncol 2018 07;7(3):CNS222018-08-29 00:00:002019-02-15 09:00:10Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 T-lymphocyte counts
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-22 / Cancer Immunol. Immunother. 2018 Nov;67(11):1777-1788
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-22 / Cancer Immunol. Immunother. 2018 Nov;67(11):1777-17882018-08-22 00:00:002019-03-25 10:40:24Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-07 / Sci Rep 2018 Aug;8(1):11800
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-07 / Sci Rep 2018 Aug;8(1):118002018-08-07 00:00:002018-08-07 00:00:00Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-31 / Sci Rep 2018 Jul;8(1):11470
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-31 / Sci Rep 2018 Jul;8(1):114702018-07-31 00:00:002019-02-15 09:00:24Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-27 / Cancer Immunol. Immunother. 2018 Oct;67(10):1545-1558
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-27 / Cancer Immunol. Immunother. 2018 Oct;67(10):1545-15582018-07-27 00:00:002019-02-15 08:47:42High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T depletion
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-26 / Ther Clin Risk Manag 2018;14:1299-1313
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-26 / Ther Clin Risk Manag 2018;14:1299-13132018-07-26 00:00:002019-02-15 08:47:37Dendritic cell vaccines for high-grade gliomas
